The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Booth is supported as a Canada Research Chair in Population Cancer Care. This work was also supported by the Canada Foundation for Innovation and the Canadian Institutes of Health Research.
Parts of this material are based on data and information provided by Cancer Care Ontario. However, the analysis, conclusions, opinions, and statements expressed herein are those of the authors and not necessarily those of Cancer Care Ontario.
This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.
Dr. Booth had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
See JNCCN.org for supplemental online content.
TournigandCAndréTAchilleE. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004;22:229–237.
KueblerJPWieandHSO'ConnellMJ. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol2007;25:2198–2204.
LabiancaRNordlingerBBerettaGD. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2013;24(Suppl 6):vi64–vi72.
BensonABIIIVenookAPBekjaii-SaabT. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2016. Accessed August 31 2016. To view the most recent version of these guidelines visitNCCN.org.
PeppercornJMWeeksJCCookEFJoffeS. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet2004;363:263–270.
TempletonAJVera-BadilloFEWangL. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol2013;24:2972–2977.
BoothCMMackillopWJ. Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA2008;300:2177–2179.
BoothCMTannockIF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer2014;110:551–555.
SanoffHKCarpenterWRMartinCF. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst2012;104:211–227.
ChagparRXingYChiangYJ. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol2012;30:972–979.
van GilsCWKoopmanMMolL. Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands. Acta Oncol2012;51:57–64.
AspinallSLGoodCBZhaoX. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer2015;15:62.
SmoragiewiczMJavaheriKRYinYGillS. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. J Gastrointest Cancer2014;45:460–465.
SanoffHKCarpenterWRFreburgerJ. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. Cancer2012;118:4309–4320.
AndréTde GramontAVernereyD. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol2015;33:4176–4187.
BoothCMNanjiSWeiX. Use and effectiveness of adjuvant chemotherapy for stage III colon cancer: a population-based study. J Natl Compr Canc Netw2016;14:47–56.
ClarkeEAMarrettLDKriegerN. Cancer registration in Ontario: a computer approach. In: JensonOMParkinDMMacLennanR eds. Cancer Registration Principles and Methods. Lyon,France: IARC; 1991:246–257.
DeyoRACherkinDCCiolMA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol1992;45:613–619.
YothersGO'ConnellMJAllegraCJ. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol2011;29:3768–3774.
ChanskyKBenedettiJMacdonaldnJS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer2005;103:1165–1171.
SloanJAGoldbergRMSargentDJ. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol2002;20:1491–1498.
KimBHBradleyTTaiJBudmanDR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology2009;76:231–238.